REVIEW ON AN ARB HAVING HIGHER ASSOCIATION LOWER DISSOCIATION INDEX FOR A RECEPTOR: A NEW TREND IN ACHIEVEMENT OF HYPERTENSION GOAL

Abstract

OLMESARTAN (angiotensin II receptor blockers (ARBs) having blood pressure lowering efficacy similar to  other antihypertensive agents. Recent large-scale, randomized, controlled clinical trials have demonstrated that ARBs offer cardiovascular and renal protective benefits independent of their effects on systemic blood pressure (BP), which make them valuable as first-line antihypertensive agents, especially in high-risk patients. However, as is the case with other antihypertensive classes, monotherapy with the first-available ARBs may not provide sufficient BP reduction to achieve currently recommended BP goals in many patients.The angiotensin II receptor blockers (ARBs) are well tolerated and demonstrate significant BP reduction. Olmesartan medoxomil, an ARB, has been well studied and achieves significant BP lowering and goal achievement with good tolerability.Olmesartan medoxomil is the latest angiotensin II receptor include once-daily dosing, an absence of significant adverse reactions, a well-tolerated side-effect profile, and a cost-effective average wholesale price. Olmesartan medoxomil is currently being used as an alternative therapeutic antihypertensive agent for patients intolerant of angiotensin-converting enzyme inhibitors(ACEIs).

Keywords: Olmesartan medoxomil, Randomized, Losartan, Valsartan, ACEIs, ARBs